News

Call for Abstracts to Present at MHSRS 2021

The call for abstracts to present a poster at this year’s Military Health System Research Symposium (MHSRS) is now open through March 31. They are planning for this year’s conference to be in person. The dates are pending, but usually are in mid- to late-August in Orlando, FL. G2G account managers will reach out separately and in your next check-in call re: assisting with a submission. Details below.

NOTE: DoD-sponsored SARS CoV-2 (COVID-19) related research will be highlighted in dedicated 2021 MHSRS breakout sessions. Oral presentations at these sessions will be by invitation only.

* The Call for Abstracts will be for posters only. COVID-19 related research abstracts submitted to sessions other that those that are focused on COVID-19 will be re-directed to the COVID-19 session leads for poster consideration.

* For 2021, a special MHSRS award category for COVID-19 research will be offered for individuals and teams.

2021 MHSRS Call for Abstracts
February 17, 2021 to March 31, 2021
The deadline will not be extended past 31 March 2021.

How to Submit a 2021 Abstract
(1) Complete the abstract submission form, (2) upload a CV, (3) upload a signed Conflict of Interest (COI) form

The abstract should be no more than 8000 characters in length. There are no format or font restrictions. No embedded tables, pictures, or videos will be accepted. Have the presenter CV and signed COI form in pdf format ready to upload when you initiate abstract submission to facilitate the submission process.

Link to submit and Abstract: https://mhsrs.amedd.army.mil/SitePages/Submit-an-Abstract.aspx

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and